Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allium CE marks prostatic stent

This article was originally published in Clinica

Executive Summary

Allium Group has CE marked its prostatic stent for sale in Europe. Used in patients with benign prostatic hyperplasia (BPH) or with advanced prostate cancer, the device has a triangular cross-section to match the contours of the prostatic urethra, and can exert varying degrees of radial force depending on the anatomy and function of the part of the urethra in which it is deployed. This means the device is more comfortable than existing stents in the long term, the Caesarea, Israel firm said. Distribution of the stent will begin during the first months of 2009.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel